A late-breaking presentation at the annual congress of the European Heart Rhythm Association (EHRA; 12–14 April 2026, Paris, France) has reaffirmed the safety and effectiveness of Boston Scientific’s Farapulse pulsed field ablation (PFA) platform, according to the company.
Within the BEAT PERS-AF study, one-year outcomes from 49 persistent atrial fibrillation (AF) patients treated with the Farapulse PFA platform—using the Farawave PFA catheter—demonstrated favourable efficacy and safety outcomes, as well as predictable and efficient procedural length.
Additionally, in line with previous data, results demonstrated a 65% efficacy rate—defined as freedom from recurrence, repeat ablation or further antiarrhythmic drug use—and a low safety event rate, with no reports of stroke, oesophageal fistulas or pulmonary vein stenosis, Boston Scientific further claims.
The company goes on to detail that these results follow last month’s CE-mark approval of its PFA platform for persistent AF. In Europe, Farapulse is now approved for the treatment of both persistent and paroxysmal AF, with the Farapoint catheter also indicated for the treatment of right atrial flutter.
“The BEAT PERS-AF study builds on the safety and efficacy profile of the Farapulse PFA platform in treating patients with persistent AF,” said Angelo Auricchio, chief medical officer for rhythm management in Europe, the Middle East and Africa (EMEA) at Boston Scientific. “These findings are consistent with prior studies, including the ADVANTAGE AF trial, and contribute to the growing body of clinical evidence supporting Farapulse. They reflect Boston Scientific’s continued commitment to advancing electrophysiology through robust science and delivering innovative, patient-focused solutions.”
